EyePoint Pharmaceuticals Stock Price

-0.14 (-1.54%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
EyePoint Pharmaceuticals Inc EYPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.14 -1.54% 8.94 18:00:37
Open Price Low Price High Price Close Price Prev Close
8.91 8.835 9.19 8.94 9.08
Bid Price Ask Price Spread News
6.28 10.95 4.67 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,322 100,884 $ 9.01 $ 909,410 337,834 0.3511 - 15.06
Last Trade Time Type Quantity Stock Price Currency
16:00:00 3,187 $ 8.94 USD

EyePoint Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 162.34M 18.16M 13.87M $ 20.36M $ - -5.50 -3.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

EyePoint Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EYPT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.1310.118.609.45219,323-0.19-2.08%
1 Month10.7011.268.609.87236,615-1.76-16.45%
3 Months11.1115.068.6011.70349,681-2.17-19.53%
6 Months0.4915.060.35114.49617,8138.451,724.49%
1 Year0.92115.060.35111.681,137,0158.02870.68%
3 Years1.7515.060.35111.81743,7887.19410.86%
5 Years3.2215.060.35111.76587,2915.72177.64%

EyePoint Pharmaceuticals Description

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.

Your Recent History
EyePoint P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.